Pharos iBio Co., Ltd.

Founded in 2016 and listed on KOSDAQ in 2023, Pharos iBio is a research and development company focused on innovative therapies for rare and intractable diseases, particularly oncology. Using its AI-driven drug discovery platform Chemiverse, the company has built a pipeline including the acute myeloid leukemia candidate Lasmotinib (PHI-101), the recurrent ovarian cancer candidate PHI-101-OC, the FAK inhibitor PHI-301, and the NRAS AML candidate PHI-501. Pharos iBio manufactures no marketed drug itself, instead pursuing conditional approval after Phase 2 trials and out-licensing of candidates as its business model, and Lasmotinib (PHI-101) received orphan drug designations from the US FDA in 2019, Korea's MFDS in 2024 (the country's 53rd such designation), and the EU EMA in 2025.

PHI-101(라스모티닙) · 급성골수성백혈병(AML) · 임상 1상 완료, CSR 수령(2025.6.30) · Received orphan drug designations from the US FDA (2019), Korea MFDS (2024, the country's 53rd such designation), and EU EMA (2025); an investigator-initiated trial (IIT) is ongoing for minimal residual disease (MRD)

PHI-101-OC · 재발성 난소암 · 임상 1상 진행 중 · Preclinical evaluation showed efficacy in cell and in vivo models regardless of BRCA mutation status; Phase 1 trial initiated November 2020

PHI-301 · 방사선 민감성 증진(FAK 저해제) · 선도물질 단계 · Under development via an exclusive license from the Korea Institute of Radiological & Medical Sciences

PHI-501 · NRAS AML / 난치성 고형암 · 임상 1상 진행 중 · Patent acquired from the Korea Institute of Science and Technology; indication expanded to refractory solid tumors using the Chemiverse AI platform